Enliven Therapeutics (ELVN) News Today $44.41 +0.72 (+1.64%) As of 12:35 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Enliven Therapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Enliven Therapeutics (NASDAQ:ELVN) Stock Price Breaks Above 200-Day Moving Average - Time to Sell?October 28 at 3:02 AM | americanbankingnews.comTD Cowen Remains a Buy on Enliven Therapeutics (ELVN)October 25 at 11:42 PM | theglobeandmail.comWhat is HC Wainwright's Estimate for ELVN Q3 Earnings?October 23, 2026 | americanbankingnews.comEnliven Therapeutics (NASDAQ:ELVN) CFO Sells $231,572.64 in StockOctober 22, 2026 | insidertrades.comBrokers Set Expectations for ELVN FY2027 EarningsOctober 22, 2026 | americanbankingnews.comEnliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 6,018 Shares of Company StockOctober 21, 2026 | marketbeat.comQ3 Earnings Forecast for ELVN Issued By HC WainwrightOctober 21, 2026 | marketbeat.comFY2027 Earnings Estimate for ELVN Issued By HC WainwrightOctober 20, 2026 | marketbeat.comHC Wainwright Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock PriceOctober 19, 2026 | americanbankingnews.comEnliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst SaysOctober 19, 2026 | marketbeat.comEnliven Therapeutics, Inc. $ELVN Stock: Assenagon Asset Management S.A. Boosts HoldingsOctober 18, 2026 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Cut to Strong Sell at Zacks ResearchOctober 15, 2026 | marketbeat.comEnliven Therapeutics, Inc. Announces Appointment of Kristine Ball to Board of Directors, Effective October 14, 2026October 15, 2026 | marketscreener.comMEnliven Therapeutics, Inc.: Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearOctober 15, 2026 | finanznachrichten.deEnliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearOctober 14, 2026 | prnewswire.comWhy Enliven Therapeutics' (ELVN) ENABLE-2 Trial Design Raises New Questions About Its CML StrategyOctober 10, 2026 | finance.yahoo.comEnliven Therapeutics Announces FDA Alignment On ENABLE-2 Pivotal Phase 3 Trial Design For Relcobatinib In Previously Treated Chronic Myeloid LeukemiaOctober 7, 2026 | marketscreener.comMEnliven Gets FDA Alignment For Phase 3 Relcobatinib Trial In Blood CancerOctober 7, 2026 | rttnews.comFDA agrees ENABLE-2 Phase III trial design for Enliven’s relcobatinibOctober 7, 2026 | yahoo.comEnliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 TrialOctober 7, 2026 | marketscreener.comMEnliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid LeukemiaOctober 6, 2026 | prnewswire.comEnliven Therapeutics (NASDAQ:ELVN) Stock Falls 4.5% Following Insider SellingOctober 6, 2026 | marketbeat.comEnliven Therapeutics (NASDAQ:ELVN) Stock: Insider J. Scott Garland Sells 13,000 SharesOctober 5, 2026 | marketbeat.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of "Moderate Buy" from BrokeragesOctober 4, 2026 | marketbeat.comThis Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayOctober 2, 2026 | benzinga.comJPMorgan Chase & Co. Begins Coverage on Enliven Therapeutics (NASDAQ:ELVN)October 1, 2026 | marketbeat.comEnliven Therapeutics, Inc. $ELVN Shares Newly Acquired by Bank of America Corp DESeptember 29, 2026 | marketbeat.comEnliven Therapeutics Insider Sold Shares Worth $303,003, According to a Recent SEC FilingSeptember 21, 2026 | marketscreener.comMEnliven Therapeutics, Inc. (ELVN)September 17, 2026 | finance.yahoo.com10 mid-cap healthcare stocks with the strongest momentum gradesSeptember 17, 2026 | msn.comEnliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comEnliven Therapeutics to Present at Upcoming Investor ConferencesSeptember 3, 2026 | prnewswire.comEnliven Therapeutics: A Clean Active-Site TKI Could Redefine CML SequencingSeptember 3, 2026 | seekingalpha.comEnliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingAugust 31, 2026 | prnewswire.comEnliven Therapeutics (NASDAQ:ELVN) CFO Sells $352,534.44 in StockAugust 20, 2026 | insidertrades.comMika Derynck Sells 158,795 Shares of Enliven Therapeutics (NASDAQ:ELVN) StockAugust 7, 2026 | insidertrades.comEnliven Therapeutics Reports Second Quarter Financial Results and Provides a Business UpdateAugust 5, 2026 | prnewswire.comProfitable biotechs strut their stuff as stock market stumblesJuly 17, 2026 | msn.comLori Anne Kunkel Sells 10,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) StockJuly 9, 2026 | insidertrades.comStocks to watch: 14 names test and tease new buy zonesJuly 8, 2026 | msn.comEnliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value LagsJuly 4, 2026 | finance.yahoo.comWhat to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%June 27, 2026 | fool.comWhat to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% RallyJune 27, 2026 | fool.comMedical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?June 24, 2026 | finance.yahoo.comInsider Selling: Enliven Therapeutics (NASDAQ:ELVN) CFO Sells 6,018 SharesJune 23, 2026 | insidertrades.comEnliven Therapeutics: Continuing The Pop Off; What Could Go Wrong?June 22, 2026 | seekingalpha.comAnalysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Twist Bioscience (TWST)June 16, 2026 | theglobeandmail.comEnliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ...June 15, 2026 | finance.yahoo.comEnliven Therapeutics, Inc. (ELVN) Presents at European Hematology Association (EHA) 2026 Congress - SlideshowJune 15, 2026 | seekingalpha.comEnliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional SharesJune 15, 2026 | prnewswire.com Enliven Therapeutics Media Mentions By Week Enliven Therapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELVN News Sentiment▼1.030.69▲Average Healthcare News Sentiment Enliven Therapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELVN Articles This Week▼84▲ELVN Articles Average Week Enliven Therapeutics Trends on MarketBeatThis week vs. last weekNew Followers3+200%Searches2+100%Page Views1,724-9% Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies BioMarin Pharmaceutical News Today Madrigal Pharmaceuticals News Today Krystal Biotech News Today Vaxcyte News Today Kymera Therapeutics News Today ImmunityBio News Today Protagonist Therapeutics News Today Spyre Therapeutics News Today TG Therapeutics News Today Arrowhead Pharmaceuticals News Today News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Enliven Therapeutics dated 10/25/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
